CIK细胞临床应用技术规范探讨

1482007422ChinMedBiotechnol,April2007,Vol.2,No.2··cytokininducedkillercellsCIKCIKLAK100[1]CIKCIK1999FDA1998CIKCIKGMP1802h2001hCIKCIKCIKCIK[2]0IFN-γ[e-mail]2007-02-252007422ChinMedBiotechnol,April2007,Vol.2,No.2149500U/ml375%CO224h1IL-2300U/mlCD310ng/mlIL-1100U/mlCIK10d[3]1520dCIK1020dCIKCD3+CD56-CD3+CD56+CIKCD3+CD56+[4]CIKMTTLDH/20:1CIKNKK56250%NKRaji30%CIKCIKCIK2100200mlCIK[5-10][11-13]CIKCIKCIK[14-15[3KPS60%68µmol/L90IU/L353µmol/L3.5×109/L80×109/L0.20CIK13IL-250U450100ml20CIK15d12d151CIKCIK[15]CIK2×1091×1010IL-2100UCIK48h3824h39CR4PR50%4MR25%50%SD25%1502007422ChinMedBiotechnol,April2007,Vol.2,No.225%PD25%32255B5cmCR1XBPR11MR1SD1PD=CR+PR/×100%CA199TNKCTLTCD364.85±2.37CD442.45±2.49CD823.82±1.45CD4/CD81.79±0.16CD2010.42±1.80KPS[1]Schmidt-WolfIG,NegrinPR,KiemHP,etal.UseofaSCIDmouse/humanlymphomamodeltoevaluatecytokine-inducedkillercellswithpotentantitumorcellactivity.JExpMed,1991,174(1):139-149.[2]LuPH,NegrinRS.AnovelpopulationofexpandedhumanCD3+CD56+cellsderivedfromTcellswithpotentinvivoantitumoractivityinmicewithseverecombinedimmunodeficiency.JImmunol,1994,153(4):1687-1696.[3]FinkeS,TrojaneckB,LefterovaP,etal.IncreaseofproliferationrateandenhancementofantitumorcytotoxicityofexpandedhumanCD3+CD56+immunologiceffectorcellsbyreceptor-mediatedtransfectionwiththeinterleukin-7gene.GeneTher,1998,5(1):31-39.[4]TongCR,HongB,QiuJY,etal.Significanceofcytogeneticandfluorescenceinsituhybridizationanalysisinevaluatingantichronicmyeloidleukemiaefficacyofdifferentimmuneeffectorcells.CancerGenetCytogenet,2002,134(1):21-24.[5]ZhuSX,ZhuJP,XuM,etal.ExperienceresearchofCIKcellsinvitroandtheclinicaleffectoftreatmenttumors.JiangsuMedJ,2006,32(11):1093.(inChinese),,,.CIK.,2006,32(11):1093.[6]BaoF,XuY,YinFH,etal.TheclinicalstudyofCIKcelladoptiveimmunotherapyformalignanttumors.LiaoningMedJ,2003,17(4):187-188.(inChinese),,,.CIK.,2003,17(4):187-188.[7]ChenFX,LiuJQ,ZhangNZ,etal.Clinicalobservationonadoptiveimmunotherapywithautologouscytokine-inducedkillercellsforadvancedmalignanttumor.ChinJCancer,2002,21(7):797-801.(inChinese),,,..,2002,21(7):797-801.[8]SunHC,TongZY.Perventivetreatmentforrecurrenceaftercurativeresectionofhepatocellularcarcinoma:aliteraturereviewofrandomizedcontroltrail.WorldJGastroenterol,2003,9(4):635-640.[9]ZhaoM,WuPH,ZhengYX,etal.Cytokinginducedkillercellfusiontolowerrecurrenceofhepatocellularcaicinomaaftertranscatheterarterialchemcembolizationsequentiallycombinedwithradiofrequencyablation:arandomizedtrial.NatlMedJChina,2006,86(26):1823-1828.(inChinese),,,..,2006,86(26):1823-1828.[10]MakiG.Exvivopurgingofstemcellautograftsusingcytotoxiccells.JHematotherStemCellRes,2001,10(4):545-551.[11]Schmidt-WolfIG,FinkeS,TrojaneckB,etal.PhaseIclinicalstudyapplyingautilogousimmunologicaleffectorcellstransfectedwiththeinterleukin-2geneinpatientswithmatastaticrenalcancer,colorectalcancerandlymphoma.BrJCancer,1999,81(6):1009-1016.[12]LeemhuisT,WellsS,ScheffoldC,etal.AphaseItrialofautologouscytokine-inducedkillercellsforthetreatmentofrelapsedHodgkindiseaseandnon-Hodgkinlymphoma.BiolBloodMarrowTransplant,2005,11(3):181-187.[13]LinnYC,HuiKM.Cytokine-inducedkillercells:NK-likeTcellswithcytotolyticspecificityagainstleukemia.LeukLymphoma,2003,44(9):1457-1462.[14]GaoY,WeiL,ChenHS,etal.AutologousadoptiveimmunotherapywithoutdestructionofinfectedcellsduringthetreatmentofchronichepatitisB.ChinJHepatol,2003,11(7):391-393.(inChinese),,,..,2003,11(7):391-393.[15]TongCR,GengYB,JiangQ,etal.Firstreportoftheeffectofauto-cytokineinducedkillersonHCVinfectioninthepatientswithleukemia.JBejingMedUni,2000,32(3):251-255.(inChinese),,,..,2000,32(3):251-255.[16]ChengX,ZhangXS,PengRQ,etal.TheeffectoftumorloadonclinicaloutcomeofCIK/IL-2therapy.ChinJClinOncol,2005,32(15):847-848,855.(inChinese),,,.CIK/IL-2.,2005,32(15):847-848,855.